What's your point? I thought you were debate the following points for oversea R&D rebate and a majority of the clinical trial needed to be done here??? Azer-Cel only recruited around 9-10 patients from November 2023 so I'm not expecting massive rebate from them. A majority of the R&D expenditure was from VAXINIA and OASIS and clearly a majority of them don't need to be done in Australia as evident by the 2023 R&D rebate.
3) The research cannot be done in Australia.
4) The costs should not exceed what would have been spent in Australia.
IMU Price at posting:
1.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)